Acceleron Pharma to Host Conference Call and Webcast to Review Updated Luspatercept Results Presented at the 21st Congress of the European Hematology Association

Management to review highlights from presentations of ongoing Phase 2 clinical trials in MDS and beta-thalassemia

CAMBRIDGE, Mass.--()--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body’s ability to rebuild and repair its own cells and tissues, today announced that the Company will host a conference call and live webcast on Friday, June 10, 2016, at 8:00 AM EDT (2:00 PM CEST) to review preliminary results from the luspatercept ongoing Phase 2 clinical trials in myelodysplastic syndromes and beta-thalassemia being presented at the 21st Congress of the European Hematology Association (EHA).

To participate by teleconference, please dial 877-312-5848 (domestic) or 253-237-1155 (international) and refer to the Acceleron EHA Congress Review. To access the live webcast, please select “Events & Presentations” in the Investor section on the Company’s website ( at least 10 minutes beforehand to ensure time for any downloads that may be required.

An archived webcast recording will be available on the Acceleron website beginning approximately two hours after the event.

About Acceleron

Acceleron discovers and develops novel therapies to treat a wide range of rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This innovative approach to drug discovery has generated four therapeutic candidates currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases, myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

For more information, please visit Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.


Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Senior Director, Investor Relations and Corporate Communications
BMC Communications LLC
Brad Miles, 646-513-3125

Recent Stories

RSS feed for Acceleron Pharma Inc.

Acceleron Pharma Inc.